Bradykinin receptor B2

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

Retrieved on: 
Thursday, April 4, 2024
Safety, CIIC, Abstract, HAE, Hereditary angioedema, Conference, Bradykinin receptor B2, Pharmaceutical industry

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Key Points: 
  • ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.
  • Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

Retrieved on: 
Wednesday, March 6, 2024
Bradykinin receptor B2, Hereditary angioedema, Real, Safety, Heredity, Treatment, Conference, HAE, Network, Abstract, National Congress, Pharmaceutical industry

ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) , to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas , to be held from March 15-17, 2024, in Panama City, Panama.

Key Points: 
  • ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of abstracts for presentation at two upcoming congresses: the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) , to be held from March 14-16, 2024, in Milan, Italy, and the 2024 HAE International (HAEi) Regional Conference Americas , to be held from March 15-17, 2024, in Panama City, Panama.
  • Details of the presentations are as follows:
    Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
    Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
    Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    2024 HAEi Regional Conference Americas, Panama City, Panama, March 15-17, 2024.
  • Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
    Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
    Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    Title: Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey
    The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations .

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Retrieved on: 
Thursday, February 22, 2024
Bradykinin receptor B2, AAAAI, ODT, Hereditary angioedema, Attack, Safety, Washington Convention Center, EST, Reason (argument), Angioedema, HAE, Death, Abstract, Journal, Walter, Asthma, Science, Patient satisfaction, American Academy, Pharmaceutical industry

CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).

Key Points: 
  • CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).
  • 34 participants were treated with double-blinded study drug (placebo or deucrictibant, 20 or 40 mg/day) for 12 weeks of treatment.
  • “These data validate the mechanism of deucrictibant to provide early and sustained protection from HAE attacks.
  • By better understanding and addressing these factors, we aspire to make our commitment to ‘pioneering science for patient choice’ a reality.”

Pharvaris to Present at the WSAAI Annual Meeting 2024

Retrieved on: 
Friday, January 26, 2024
HAE, Hereditary angioedema, Treatment, Bradykinin receptor B2, Safety, Abstract, Pharmaceutical industry

ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.

Key Points: 
  • ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024, to be held from February 4-8, 2024, at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii.
  • Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
    The posters will be made available throughout the conference and on the Investors section of the Pharvaris website at the beginning of the poster session at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Retrieved on: 
Friday, January 5, 2024
Hereditary angioedema, Quality of life, Conference, Toxicology, Reason (argument), IND, Scale, Research, FDA, Executive Committee, Bradykinin receptor B2, Attack, Patient satisfaction, Angioedema, Trial of the century, Incidence, American Academy, Annual general meeting, AAAAI, Doctor of Philosophy, ACE, Virtual, Safety, Publication, ODT, Therapy, HAE, General Atlantic, Pharmaceutical industry

“Pharvaris enters the new year having demonstrated deucrictibant’s potential to be the preferred option for both the prevention and treatment of HAE attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris.

Key Points: 
  • “Pharvaris enters the new year having demonstrated deucrictibant’s potential to be the preferred option for both the prevention and treatment of HAE attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris.
  • The next years will be incredibly important to the company, and Jochen’s continued strategic guidance will be invaluable.”
    Anticipated initiation of RAPIDe-3 within 1H2024.
  • Jochen Knolle, Ph.D., co-founder of Pharvaris, transitions to strategic advisor to the CEO and Executive Committee.
  • I look forward to continuing to contribute to the strategic transformation of Pharvaris in my new capacity.”
    Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

Retrieved on: 
Saturday, March 18, 2023
Attack, Hereditary angioedema, Safety, Bradykinin receptor B2, Softgel, II, Pain, HAE, Oral, United Kingdom, Conference, Pharmaceutical industry

The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.

Key Points: 
  • The time required for preparation and administration, as well as potential occurrence of pain, discomfort, or other injection site reactions can lead to treatment delays or untreated HAE symptoms.
  • 74 participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
  • Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, 20 mg=10.7%, 30 mg=6.5%, placebo=60.8%).
  • The presentation slides will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

Retrieved on: 
Friday, February 24, 2023
Translational medicine, Pharmacology, Safety, Bradykinin receptor B2, American Academy, Softgel, Fraunhofer Society, Hereditary angioedema, United Kingdom, AAAAI, Oral, Attack, II, HAE, Berlin, Bradykinin, Poster, Pharmaceutical industry, Dermatology, Immunology

Today, people living with HAE must inject themselves either subcutaneously or intravenously when treating HAE swellings.

Key Points: 
  • Today, people living with HAE must inject themselves either subcutaneously or intravenously when treating HAE swellings.
  • 74 participants were enrolled and 62 of them experienced 147 qualifying HAE attacks that were treated with double-blinded study drug (either placebo or PHVS416 10, 20, or 30 mg doses).
  • Participants on PHVS416 also used substantially less rescue medication compared to placebo (10 mg=18.9%, 20 mg=10.7%, 30 mg=6.5%, placebo=60.8%).
  • Following the data presentation on February 26, the poster and audio recording will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations .